Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Novus Therapeutics, Inc. (Note: The input metadata references Eledon Pharmaceuticals, but the filing text explicitly identifies Novus Therapeutics, Inc.) on May 12, 2020. The company is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol NVUS.
Key Financial Metrics
This filing is a Current Report regarding corporate governance and stockholder votes. It does not provide financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes and Stockholder Votes
Stockholders voted on five proposals at the Annual Meeting. The results were as follows:
- Director Elections: Two Class III directors, Gregory J. Flesher and Gary A. Lyons, were elected for three-year terms. Both received significant "For" votes (approx. 4.08 million each) against "Withhold" votes (approx. 1.92 million each), with 6,888,247 broker non-votes.
- Independent Auditor Ratification: Stockholders ratified the appointment of KMJ Korbin & Company LLP. Votes: 12,199,557 For, 122,477 Against, 574,246 Abstain.
- Reverse Stock Split: Stockholders approved an amendment to the Restated Certificate of Incorporation to effect a reverse stock split. The ratio will be determined by the Board, ranging from 1-for-10 to 1-for-30. Votes: 11,636,557 For, 762,853 Against, 496,870 Abstain.
- Executive Compensation (Say-on-Pay): Advisory approval was granted. Votes: 4,760,047 For, 638,351 Against, 609,635 Abstain.
- Frequency of Say-on-Pay Votes: Stockholders voted to hold future advisory votes on executive compensation every three years. Votes: 3,065,237 for 3 Years, 2,204,832 for 1 Year, 110,849 for 2 Years.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, outlook, or management commentary regarding business operations or future financial performance. The only forward-looking determination noted is the Board's decision to conduct future advisory votes on executive compensation every three years, consistent with the stockholder vote.
Important Facts for Investor Verification
- Verify the specific reverse stock split ratio (between 1-for-10 and 1-for-30) once announced by the Board of Directors.
- Confirm the impact of the reverse stock split on the number of outstanding shares and share price.
- Note the high volume of broker non-votes (6,888,247) on director elections and compensation frequency, indicating a significant portion of shares were held in street name without voting instructions on those specific items.
- Review subsequent filings for financial performance data, as this 8-K contains no financial statements.